Comparative Pharmacology
Head-to-head clinical analysis: AK FLUOR 25 versus BLUDIGO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AK FLUOR 25 versus BLUDIGO.
AK-FLUOR 25% vs BLUDIGO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium fluorescein absorbs light in the blue spectrum (465-490 nm) and emits yellow-green fluorescence (520-530 nm), enabling visualization of the retinal and choroidal vasculature by highlighting areas of vascular leakage, staining defects, or filling defects.
BLUDIGO is a selective inhibitor of the hedgehog signaling pathway, specifically targeting the Smoothened (SMO) receptor, thereby suppressing the transcription of glioma-associated oncogene (GLI) family members and downstream target genes involved in cell proliferation and survival.
Intravenous administration: 5-15 mg/kg as a single bolus injection over 1-2 minutes. For ophthalmic use: 1-2 drops of 2% fluorescein solution topically.
Intravenous (IV) 5 mg/kg every 8 hours, infused over 90 minutes on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle.
None Documented
None Documented
Terminal half-life: 1-2 minutes (fluorescence decay); clinical context: transient plasma fluorescence, minimal systemic accumulation
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Renal: >90% unchanged within 24-48 hours; <10% fecal via biliary elimination
Primarily renal (70-80% unchanged) and biliary (15-20% as glucuronide conjugates); fecal excretion <5%.
Category C
Category C
Diagnostic Dye
Diagnostic Dye